BR112023014719A2 - Novas nucleases quiméricas e manipuladas - Google Patents

Novas nucleases quiméricas e manipuladas

Info

Publication number
BR112023014719A2
BR112023014719A2 BR112023014719A BR112023014719A BR112023014719A2 BR 112023014719 A2 BR112023014719 A2 BR 112023014719A2 BR 112023014719 A BR112023014719 A BR 112023014719A BR 112023014719 A BR112023014719 A BR 112023014719A BR 112023014719 A2 BR112023014719 A2 BR 112023014719A2
Authority
BR
Brazil
Prior art keywords
nucleases
chimeric
engineered
new chimeric
disclosed
Prior art date
Application number
BR112023014719A
Other languages
English (en)
Inventor
Alan Brooks
C Thomas Brian
Christopher Brown
Cristina Butterfield
Greg Cost
Jyun-Liang Lin
M Temoche-Diaz Morayma
Rebecca Lamothe
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of BR112023014719A2 publication Critical patent/BR112023014719A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

novas nucleases quiméricas e manipuladas. são divulgados, neste documento, nucleases manipuladas e sistemas de nuclease, incluindo nucleases quiméricas e sistemas de nuclease quimérica. as nucleases manipuladas e quiméricas divulgadas neste documento incluem nuclease guiada por ácido nucleico. são divulgados adicionalmente, neste documento, métodos de geração de nucleases manipuladas e métodos de uso das mesmas.
BR112023014719A 2021-01-22 2022-01-21 Novas nucleases quiméricas e manipuladas BR112023014719A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163140620P 2021-01-22 2021-01-22
US202163237484P 2021-08-26 2021-08-26
PCT/US2022/013396 WO2022159758A1 (en) 2021-01-22 2022-01-21 Novel engineered and chimeric nucleases

Publications (1)

Publication Number Publication Date
BR112023014719A2 true BR112023014719A2 (pt) 2023-12-05

Family

ID=82549895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023014719A BR112023014719A2 (pt) 2021-01-22 2022-01-21 Novas nucleases quiméricas e manipuladas

Country Status (10)

Country Link
US (1) US20230416710A1 (pt)
EP (1) EP4281554A1 (pt)
JP (1) JP2024504981A (pt)
KR (1) KR20230134543A (pt)
AU (1) AU2022210762A1 (pt)
BR (1) BR112023014719A2 (pt)
CA (1) CA3205865A1 (pt)
GB (1) GB2610711B (pt)
MX (1) MX2023008629A (pt)
WO (1) WO2022159758A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011039A (es) 2020-03-06 2022-12-13 Metagenomi Inc Sistemas crispr clase ii tipo v.
WO2023028348A1 (en) * 2021-08-27 2023-03-02 Metagenomi, Inc. Enzymes with ruvc domains
WO2024026499A2 (en) * 2022-07-29 2024-02-01 Metagenomi, Inc. Class ii, type v crispr systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103153A1 (en) * 2013-12-31 2015-07-09 The Regents Of The University Of California Cas9 crystals and methods of use thereof
WO2019051278A1 (en) * 2017-09-07 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University NUCLEASE SYSTEMS FOR GENETIC ENGINEERING
EP3894550A4 (en) * 2018-12-14 2023-01-04 Pioneer Hi-Bred International, Inc. NEW CRISPR-CAS SYSTEMS FOR GENOME EDITING
CA3241703A1 (en) * 2019-02-14 2020-08-20 Metagenomi, Inc. Enzymes with ruvc domains
US10913941B2 (en) * 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
WO2021226363A1 (en) * 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
JP2023540797A (ja) * 2020-09-11 2023-09-26 メタゲノミ，インコーポレイテッド 塩基編集酵素
CA3210361A1 (en) * 2021-03-19 2022-09-22 Brian Thomas Multiplex editing with cas enzymes

Also Published As

Publication number Publication date
CA3205865A1 (en) 2022-07-28
EP4281554A1 (en) 2023-11-29
US20230416710A1 (en) 2023-12-28
WO2022159758A1 (en) 2022-07-28
GB202215621D0 (en) 2022-12-07
GB2610711A (en) 2023-03-15
AU2022210762A1 (en) 2023-08-24
GB2610711B (en) 2023-08-02
MX2023008629A (es) 2023-10-25
JP2024504981A (ja) 2024-02-02
KR20230134543A (ko) 2023-09-21

Similar Documents

Publication Publication Date Title
BR112023014719A2 (pt) Novas nucleases quiméricas e manipuladas
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
EA201991369A1 (ru) Модифицированные направляющие рнк
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2020004830A (es) Medios y metodo para preparar vectores virales y usos de los mismos.
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX2020009330A (es) Pares de citocinas/receptores ortogonales biologicamente relevantes.
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
SA519401379B1 (ar) علاج فيروس مرتبط بغدة لمرض هنتنجتون
AR102420A1 (es) Sitios de integración en celulas cho y sus usos
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
AR108611A1 (es) Anticuerpos anti-cd40 y sus usos
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
BR112015030972A8 (pt) células sc-beta e composições e métodos para geração das mesmas
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
BR112017018940A2 (pt) anticorpos sítio-específicos projetados e métodos de uso
MX2019013370A (es) Constructos de anticuerpos de ácidos nucleicos optimizados.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof